Near-infrared compounds for visualizing enzymatic activity in living organisms

New fluorescent probes developed that can help clinicians pinpoint cancer metastases

New chemical compounds developed by CCR researchers and clinicians are safe and highly effective in fluorescently highlighting microscopic metastases. The new compounds could have great utility in complex living systems based on experiments done in mouse models of metastatic human ovarian cancer. Read more...

harvested GIST tissue

Study evaluates, treats, and follows patients with gastrointestinal stromal tumors

Dec 31, 2020

More than half of all gastrointestinal stromal tumors (GISTs) start in the stomach, but they can start anywhere in the GI tract. Andrew M. Blakely, M.D., Assistant Research Physician in the Surgical Oncology Program, is leading a study of GIST that could benefit current and future patients. Read more...

Immunotherapy agents

New clinical trial studies immunotherapy combination for metastatic breast cancer

Dec 29, 2020

Fatima Karzai, M.D., Associate Research Physician in the Genitourinary Malignancies Branch, is leading a study in adults with breast cancer that has spread to other places in the body. Researchers want to see if a combination of four drugs, which includes immunotherapy, can shrink the tumors of metastatic breast cancer. Read more...

cell proliferation

Clinical trial studies therapy for adults with BRAF-mutant hairy cell leukemia

Dec 16, 2020

Adults with BRAF-mutant hairy cell leukemia, that did not respond to or came back after treatment, may be eligible to participate in a clinical trial at the NIH Clinical Center. Researchers want to see if combining encorafenib and binimetinib has an improved response rate than other drugs previously used to treat HCL. Read more...

liver bacteria

New connection between gut microbes and liver cancer uncovered in mice

Dec 15, 2020

Researchers have uncovered a mechanism by which gut microbes can influence the immune response against nearby liver tumors in mice. The new findings could potentially explain why some people with liver or gut diseases, such as primary sclerosing cholangitis and colitis, tend to be more susceptible to cholangiocarcinoma. Read more...

breast cancer cells

Immunotherapy combination tested for advanced/metastatic solid tumors

Dec 14, 2020

Adults with locally advanced or metastatic solid tumors that cannot be treated with surgery may be eligible to participate in a clinical trial at the NIH Clinical Center. James L. Gulley, M.D., Ph.D., Chief of the Genitourinary Malignancies Branch, is leading a study exploring several different combinations of immunotherapies to see if they improve responses in people with cancer. Read more...

T cell analysis

Analysis of T cells from melanoma patients uncovers characteristics leading to cancer regression

Dec 10, 2020

CCR researchers used state-ot-the-art analytic techniques to determine characteristics of cells used in effective adoptive T cell therapy (ACT) in patients with advanced melanoma. This new information opens the door to manufacturing these cells in the laboratory and using them in immunotherapy for common cancers, including liver, breast, prostate, and colon cancer. Read more...

cell proliferation

Clinical trial evaluates therapy for adults with relapsed/refractory HCL

Dec 9, 2020

Robert J. Kreitman, M.D., Senior Investigator in the Laboratory of Molecular Biology, is leading a study of a treatment for hairy cell leukemia (HCL). The goal of this study is to determine the overall rate of response to binimetinib, an MEK inhibitor, in patients with HCL who do not have a BRAF gene mutation. Read more...

Cervical Cancer Stage IVA

Treatment for women with advanced, untreated cervical cancer tested in new clinical trial

Dec 7, 2020

Women 18 and older with previously untreated advanced cervical cancer may be eligible to participate in a clinical trial at the NIH Clinical Center. Christian S. Hinrichs, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is leading a study of a treatment called induction immunotherapy that uses the patient’s own T cells (immune cells) to attack their cancer cells. Read more...

Lung Cancer, Stage IIIB (1)

Clinical trial studies drug combination for EGFR-mutated adenocarcinomas

Dec 3, 2020

Adults with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer that has transformed to small cell lung cancer or a neuroendocrine tumor may be eligible to participate in a clinical trial at the NIH Clinical Center. Anish Thomas, M.B.B.S., M.D., NIH Lasker Clinical Research Scholar in the Developmental Therapeutics Branch, is leading a trial testing a drug combination to treat these kinds of tumors. Read more...

NC410 binds to tumor-associated ligands

Clinical trial evaluates therapy for advanced or metastatic solid tumors

Nov 30, 2020

Marijo Bilusic, M.D., Ph.D., Associate Research Physician in the Genitourinary Malignancies Branch, is leading NCI’s participation in a multicenter study for adults with advanced or metastatic solid (non-blood) tumors that have not responded to standard treatments. This phase 1 study will evaluate a therapy, NC410, for any serious side effects and determine the best dose that will achieve an antitumor response. Read more...

Pages